Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

An Integrated Safety Analysis of Infants and Children with Symptomatic Spinal Muscular Atrophy (SMA) Treated with Nusinersen in Seven Clinical Trials.

Darras BT, Farrar MA, Mercuri E, Finkel RS, Foster R, Hughes SG, Bhan I, Farwell W, Gheuens S.

CNS Drugs. 2019 Aug 16. doi: 10.1007/s40263-019-00656-w. [Epub ahead of print]

PMID:
31420846
2.

Nusinersen in later-onset spinal muscular atrophy: Long-term results from the phase 1/2 studies.

Darras BT, Chiriboga CA, Iannaccone ST, Swoboda KJ, Montes J, Mignon L, Xia S, Bennett CF, Bishop KM, Shefner JM, Green AM, Sun P, Bhan I, Gheuens S, Schneider E, Farwell W, De Vivo DC; ISIS-396443-CS2/ISIS-396443-CS12 Study Groups.

Neurology. 2019 May 21;92(21):e2492-e2506. doi: 10.1212/WNL.0000000000007527. Epub 2019 Apr 24.

3.

Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy.

Mercuri E, Darras BT, Chiriboga CA, Day JW, Campbell C, Connolly AM, Iannaccone ST, Kirschner J, Kuntz NL, Saito K, Shieh PB, Tulinius M, Mazzone ES, Montes J, Bishop KM, Yang Q, Foster R, Gheuens S, Bennett CF, Farwell W, Schneider E, De Vivo DC, Finkel RS; CHERISH Study Group.

N Engl J Med. 2018 Feb 15;378(7):625-635. doi: 10.1056/NEJMoa1710504.

4.

Clinical Development of Aducanumab, an Anti-Aβ Human Monoclonal Antibody Being Investigated for the Treatment of Early Alzheimer's Disease.

Budd Haeberlein S, O'Gorman J, Chiao P, Bussière T, von Rosenstiel P, Tian Y, Zhu Y, von Hehn C, Gheuens S, Skordos L, Chen T, Sandrock A.

J Prev Alzheimers Dis. 2017;4(4):255-263. doi: 10.14283/jpad.2017.39.

PMID:
29181491
5.

Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy.

Finkel RS, Mercuri E, Darras BT, Connolly AM, Kuntz NL, Kirschner J, Chiriboga CA, Saito K, Servais L, Tizzano E, Topaloglu H, Tulinius M, Montes J, Glanzman AM, Bishop K, Zhong ZJ, Gheuens S, Bennett CF, Schneider E, Farwell W, De Vivo DC; ENDEAR Study Group.

N Engl J Med. 2017 Nov 2;377(18):1723-1732. doi: 10.1056/NEJMoa1702752.

6.

Safety and efficacy of natalizumab in patients with acute ischaemic stroke (ACTION): a randomised, placebo-controlled, double-blind phase 2 trial.

Elkins J, Veltkamp R, Montaner J, Johnston SC, Singhal AB, Becker K, Lansberg MG, Tang W, Chang I, Muralidharan K, Gheuens S, Mehta L, Elkind MSV.

Lancet Neurol. 2017 Mar;16(3):217-226. doi: 10.1016/S1474-4422(16)30357-X. Epub 2017 Feb 15.

PMID:
28229893
7.

Brief Report: Role of Thymic Reconstitution in the Outcome of AIDS-Related PML.

Chalkias SG, Gheuens S, Bord E, Batson S, Koralnik IJ.

J Acquir Immune Defic Syndr. 2015 Dec 1;70(4):357-61. doi: 10.1097/QAI.0000000000000754.

8.

Predictors of survival and functional outcomes in natalizumab-associated progressive multifocal leukoencephalopathy.

Dong-Si T, Gheuens S, Gangadharan A, Wenten M, Philip J, McIninch J, Datta S, Richert N, Bozic C, Bloomgren G, Richman S, Weber T, Clifford DB.

J Neurovirol. 2015 Dec;21(6):637-44. doi: 10.1007/s13365-015-0316-4. Epub 2015 Mar 14.

9.

Outcome and survival of asymptomatic PML in natalizumab-treated MS patients.

Dong-Si T, Richman S, Wattjes MP, Wenten M, Gheuens S, Philip J, Datta S, McIninch J, Bozic C, Bloomgren G, Richert N.

Ann Clin Transl Neurol. 2014 Oct;1(10):755-64. doi: 10.1002/acn3.114. Epub 2014 Oct 9.

10.

Immune reconstitution after allogeneic hematopoietic stem cell transplantation is associated with selective control of JC virus reactivation.

Tan CS, Broge TA Jr, Ngo L, Gheuens S, Viscidi R, Bord E, Rosenblatt J, Wong M, Avigan D, Koralnik IJ.

Biol Blood Marrow Transplant. 2014 Jul;20(7):992-9. doi: 10.1016/j.bbmt.2014.03.018. Epub 2014 Mar 27.

11.

Natalizumab-associated progressive multifocal leukoencephalopathy in a patient with multiple sclerosis: a postmortem study.

Wüthrich C, Popescu BF, Gheuens S, Marvi M, Ziman R, Denq SP, Tham M, Norton E, Parisi JE, Dang X, Lucchinetti CF, Koralnik IJ.

J Neuropathol Exp Neurol. 2013 Nov;72(11):1043-51. doi: 10.1097/NEN.0000000000000005.

12.

Hyperperfusion in progressive multifocal leukoencephalopathy is associated with disease progression and absence of immune reconstitution inflammatory syndrome.

Khoury MN, Gheuens S, Ngo L, Wang X, Alsop DC, Koralnik IJ.

Brain. 2013 Nov;136(Pt 11):3441-50. doi: 10.1093/brain/awt268. Epub 2013 Oct 1.

13.

A game of viral hide and seek: miliary PML masquerading as EBV encephalitis in an HIV+ patient.

Gheuens S, Buggy BP, Tlomak W, Wüthrich C, Koralnik IJ.

Clin Neurol Neurosurg. 2013 Sep;115(9):1861-3. doi: 10.1016/j.clineuro.2013.02.020. Epub 2013 Mar 25. No abstract available.

14.

Simultaneous PML-IRIS after discontinuation of natalizumab in a patient with MS.

Marousi S, Travasarou M, Karageorgiou CE, Gheuens S, Koralnik IJ.

Neurology. 2012 Nov 20;79(21):2160; author reply 2160. doi: 10.1212/01.wnl.0000423208.11698.16. No abstract available.

PMID:
23170016
15.

Progressive multifocal leukoencephalopathy: why gray and white matter.

Gheuens S, Wüthrich C, Koralnik IJ.

Annu Rev Pathol. 2013 Jan 24;8:189-215. doi: 10.1146/annurev-pathol-020712-164018. Epub 2012 Oct 18. Review.

PMID:
23092189
16.

Metabolic profile of PML lesions in patients with and without IRIS: an observational study.

Gheuens S, Ngo L, Wang X, Alsop DC, Lenkinski RE, Koralnik IJ.

Neurology. 2012 Sep 4;79(10):1041-8. doi: 10.1212/WNL.0b013e318268465b. Epub 2012 Aug 22.

17.

Increased program cell death-1 expression on T lymphocytes of patients with progressive multifocal leukoencephalopathy.

Tan CS, Bord E, Broge TA Jr, Glotzbecker B, Mills H, Gheuens S, Rosenblatt J, Avigan D, Koralnik IJ.

J Acquir Immune Defic Syndr. 2012 Jul 1;60(3):244-8. doi: 10.1097/QAI.0b013e31825a313c.

18.

Simultaneous PML-IRIS after discontinuation of natalizumab in a patient with MS.

Gheuens S, Smith DR, Wang X, Alsop DC, Lenkinski RE, Koralnik IJ.

Neurology. 2012 May 1;78(18):1390-3. doi: 10.1212/WNL.0b013e318253d61e. Epub 2012 Apr 18.

19.
20.

Role of CD4+ and CD8+ T-cell responses against JC virus in the outcome of patients with progressive multifocal leukoencephalopathy (PML) and PML with immune reconstitution inflammatory syndrome.

Gheuens S, Bord E, Kesari S, Simpson DM, Gandhi RT, Clifford DB, Berger JR, Ngo L, Koralnik IJ.

J Virol. 2011 Jul;85(14):7256-63. doi: 10.1128/JVI.02506-10. Epub 2011 May 4.

21.

Delayed akinetic catatonic mutism following methadone overdose.

Gheuens S, Michotte A, Flamez A, De Keyser J.

Neurotoxicology. 2010 Dec;31(6):762-4. doi: 10.1016/j.neuro.2010.07.007. Epub 2010 Aug 3.

PMID:
20688102
22.

Role of human leukocyte antigen class I alleles in progressive multifocal leukoencephalopathy.

Gheuens S, Fellay J, Goldstein DB, Koralnik IJ.

J Neurovirol. 2010 Feb;16(1):41-7. doi: 10.3109/13550280903552438.

23.

Progressive multifocal leukoencephalopathy in individuals with minimal or occult immunosuppression.

Gheuens S, Pierone G, Peeters P, Koralnik IJ.

J Neurol Neurosurg Psychiatry. 2010 Mar;81(3):247-54. doi: 10.1136/jnnp.2009.187666. Epub 2009 Oct 14. Review.

24.

In vivo modulatory action of extracellular glutamate on the anticonvulsant effects of hippocampal dopamine and serotonin.

Clinckers R, Gheuens S, Smolders I, Meurs A, Ebinger G, Michotte Y.

Epilepsia. 2005 Jun;46(6):828-36.

Supplemental Content

Loading ...
Support Center